指南与共识泌尿男性生殖肿瘤

转移性去势抵抗性前列腺癌的系统治疗:ASCO 动态指南 2026.1 版

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.
指南 / 共识 · J Clin Oncol · 2026-01-20

该文为 ASCO 动态指南 2026.1 版的方法学说明,针对转移性去势抵抗性前列腺癌系统治疗领域,由常设专家组持续系统检索文献并定期更新推荐。原文未报告具体推荐条款、研究数据或样本量。

要点

  • ASCO 动态指南由常设专家组持续系统检索文献并定期更新推荐。
  • 本版针对转移性去势抵抗性前列腺癌的系统治疗。
  • 动态指南不替代临床医生独立专业判断,需考虑患者个体差异。

核心结论

  • ASCO 针对转移性去势抵抗性前列腺癌系统治疗制定动态指南,按计划定期更新推荐。

研究设计与样本

  • 由常设专家组持续系统检索健康文献,按 ASCO 指南方法学手册定期更新。

临床怎么用

  • 临床医生可参考该动态指南获取转移性去势抵抗性前列腺癌系统治疗的最新推荐。
  • 应用时不应替代医生独立专业判断,并需考虑患者个体差异。

局限性

  • 动态指南不替代治疗医生的独立专业判断,也不涵盖患者个体差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found at www.asco.org/genitourinary-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Taplin ME, Riaz IB, Rumble RB, et al. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1. J Clin Oncol. 2026. PMID: 41557978. doi:10.1200/JCO-25-02693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。